HONG KONG, Feb. 7, 2018 /PRNewswire/ -- China Cord
Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), leading
cord blood banking operator in China, today announced that the Board of
Directors of the Company (the "Board") has approved seeking
shareholder approval regarding the change of the Company's name
from "China Cord Blood Corporation" to "Global Cord Blood Corporation" ("Change of Name"). The Board
believes that the Change of Name better reflects the future
development direction and business strategy of the Company. The
Company plans to hold an extraordinary general meeting ("EGM") for
shareholders to approve the Change of Name at its Hong Kong office at 48/F, Bank of China Tower,
1 Garden Road, Central, Hong Kong,
at 8:00 p.m. Hong Kong Time on
March 16, 2018 (8:00 a.m. U.S. Eastern Daylight Time on March 16, 2018).
Shareholders of record as of February 27, 2018 will be
entitled to receive notice of and vote at the EGM. Shareholders may
request a meeting notice, proxy statement free of charge by
contacting ir@chinacordbloodcorp.com.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses.
Under current PRC government regulations, only one licensed cord
blood banking operator is permitted to operate in each licensed
region and no new licenses will be granted before 2020 in addition
to the seven licenses authorized as of today. China Cord
Blood Corporation provides cord blood collection, laboratory
testing, hematopoietic stem cell processing, and stem cell storage
services. For more information, please visit our website at
http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the U.S.
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/china-cord-blood-corporation-to-change-corporate-name-to-global-cord-blood-corporation-300594281.html
SOURCE China Cord Blood Corporation